U.S. Markets close in 3 hrs 27 mins
  • S&P 500

    4,234.94
    -12.50 (-0.29%)
     
  • Dow 30

    34,231.34
    -248.26 (-0.72%)
     
  • Nasdaq

    14,116.49
    +47.06 (+0.33%)
     
  • Russell 2000

    2,333.45
    -2.36 (-0.10%)
     
  • Crude Oil

    71.42
    +0.51 (+0.72%)
     
  • Gold

    1,865.60
    -14.00 (-0.74%)
     
  • Silver

    28.08
    -0.07 (-0.23%)
     
  • EUR/USD

    1.2127
    +0.0021 (+0.1698%)
     
  • 10-Yr Bond

    1.4940
    +0.0320 (+2.19%)
     
  • Vix

    16.74
    +1.09 (+6.96%)
     
  • GBP/USD

    1.4116
    -0.0000 (-0.0014%)
     
  • USD/JPY

    109.9920
    +0.3570 (+0.3256%)
     
  • BTC-USD

    40,283.40
    +3,344.42 (+9.05%)
     
  • CMC Crypto 200

    1,008.87
    +40.02 (+4.13%)
     
  • FTSE 100

    7,146.68
    +12.62 (+0.18%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

What Type Of Shareholders Make Up Constellation Pharmaceuticals, Inc.'s (NASDAQ:CNST) Share Registry?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

Every investor in Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that used to be publicly owned tend to have lower insider ownership.

Constellation Pharmaceuticals isn't enormous, but it's not particularly small either. It has a market capitalization of US$1.4b, which means it would generally expect to see some institutions on the share registry. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholder can tell us about Constellation Pharmaceuticals.

View our latest analysis for Constellation Pharmaceuticals

NasdaqGS:CNST Ownership Breakdown July 6th 2020
NasdaqGS:CNST Ownership Breakdown July 6th 2020

What Does The Institutional Ownership Tell Us About Constellation Pharmaceuticals?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Constellation Pharmaceuticals already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Constellation Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.

NasdaqGS:CNST Earnings and Revenue Growth July 6th 2020
NasdaqGS:CNST Earnings and Revenue Growth July 6th 2020

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. It would appear that 7.7% of Constellation Pharmaceuticals shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. The company's largest shareholder is The Column Group LLC, with ownership of 13%. VR Adviser, LLC is the second largest shareholder owning 8.5% of common stock, and Avoro Capital Advisors LLC holds about 7.7% of the company stock.

We also observed that the top 8 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Constellation Pharmaceuticals

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our data suggests that insiders own under 1% of Constellation Pharmaceuticals, Inc. in their own names. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around US$7.4m worth of shares (at current prices). Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

General Public Ownership

With a 16% ownership, the general public have some degree of sway over CNST. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With a stake of 21%, private equity firms could influence the CNST board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Constellation Pharmaceuticals (1 is concerning!) that you should be aware of before investing here.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.